Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
OPILL is a norgestrel-based oral contraceptive tablet approved in 1973 for pregnancy prevention. It is a progestin-only pill (mini-pill) that works by altering cervical mucus and endometrial conditions to prevent fertilization. This product represents a foundational hormonal contraceptive in women's health.
With LOE approaching in mid-2026, commercial teams face contraction; focus shifts to generic transition planning and niche positioning against newer progestin-only alternatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African Women
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on OPILL at Laboratoire Aguettant? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moOPILL offers limited current career opportunity with zero linked job openings and imminent LOE. Professionals considering this role should expect a short-term focus on market defense and transition management rather than growth initiatives.